AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMBBiotechnology
+$0.25 today
- Market cap
- $286.62M
- Beta
- 2.62
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$1.28
Volume 0.13M
Average 0.14M
AGMB Net Change in Cash
Combined operating, investing, financing, and currency effects on the cash balance during the period.
AgomAb Therapeutics N.V. American Depositary SharesNASDAQ: AGMB
Net Change in Cash · Q4 FY2024 · quarter ended Dec 2024
Net change in cash of €68.86M in Q4 FY2024
Q4 FY2024 net change in cash was €68.86M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Change in Cash history
Currency unavailable · from the cash flow
No Net Change in Cash data reported for this period type.
Net Change in Cash vs competitors
How AGMB compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $149.83M USD | +233.4% | — | 64.5% | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | $88.34M USD | +2748.7% | +2.1% | 1194.1% |
| LTM Mar 2026 | $46.82M USD | +1495.8% | +11.7% | — | |
| LTM Mar 2026 | $1.7M USD | -69.1% | — | 20.3% | |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | — | — | — | — | — |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — | — |
| Peer median (excluding AGMB) | — | +864.6% | +6.9% | 64.5% | |
Competitors are the stored peer set for AGMB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
AgomAb Therapeutics N.V. American Depositary Shares
NASDAQ:AGMB
Intrinsic Alpha fair value
Locked
Current Price
$5.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.